Österreich

Neuigkeiten aus dem Hauptsitz von Tokio

Die Pressemitteilungen werden von der FUJIFILM Corporation in Japan herausgegeben.
Fujifilm kann nicht versichern, dass die von diesen Mitteilungen betroffenen Artikel in allen Ländern und Teilen dieser Welt käuflich erwerbbar sind.

Bitte beachten Sie, dass der Inhalt dieser Website zum Zeitpunkt der Pressemitteilung als solcher Gültigkeit hat und ohne vorherige Ankündigung geändert werden kann. Die in der jeweiligen Mitteilung veröffentlichten Informationen, einschließlich der Verfügbarkeit von Artikeln, Spezifikationen, Preise und Kontakte, sind die zum Zeitpunkt der Veröffentlichung geltenden.

Feb 29, 2024
FUJIFILM Diosynth Biotechnologies Announces Renewable Energy PPA with Better Energy for Denmark Manufacturing Site
News Release Bio-CDMO CDMO Sustainability
Dez 5, 2023
Fujifilm to Invest USD 200 Million to Expand Cell Therapy Development and Manufacturing Capabilities
News Release Bio-CDMO CDMO Life Sciences
Nov 8, 2023
FUJIFILM Diosynth Biotechnologies Announces First Tenant for New Manufacturing Facility 
News Release Bio-CDMO CDMO
Jun 6, 2023
Fujifilm to Enhance Commercial Presence in Asia for Biologics and Advanced Therapies Contract Services 
News Release Bio-CDMO CDMO
Mär 31, 2023
Transfer of FUJIFILM Healthcare Systems’ electronic medical record and medical-receipt systems related business to PHC Holdings’ subsidiary
News Release Healthcare IT
Dez 20, 2022
Fujifilm Announces Asset Purchase Agreement with Inspirata, Inc. to acquire the company’s Digital Pathology Business
News Release M&A, Investment Healthcare IT
Dez 14, 2022
Fujifilm Invests in PhenoVista Biosciences from its Life Sciences Corporate Venture Capital Fund
News Release Regenerative Medicine M&A, Investment
Okt 6, 2022
Fujifilm to establish its first Bio-CDMO site in Japan
News Release Bio-CDMO CDMO M&A, Investment
Jun 30, 2022
Fujifilm to Invest USD 1.6 billion to enhance and expand its global offering of cell culture manufacturing services
News Release Bio-CDMO CDMO M&A, Investment
Apr 5, 2022
Fujifilm Completes Acquisition of a Dedicated Cell Therapy Manufacturing Facility from Atara Biotherapeutics, Inc.
News Release M&A, Investment Bio-CDMO CDMO
Mär 22, 2022
Transfer of FUJIFILM Toyama Chemical's Radiopharmaceutical Business
Amendment in relation to a return of domestic marketing rights for a product
News Release Pharmaceuticals
Jan 26, 2022
Fujifilm Expands its Advanced Therapies CDMO Business with the Acquisition of a Dedicated Cell Therapy Manufacturing Facility from Atara Biotherapeutics, Inc.
News Release M&A, Investment Bio-CDMO CDMO
Sep 2, 2021
Transfer of FUJIFILM Toyama Chemical's Radiopharmaceutical Business to PeptiDream
News Release Pharmaceuticals
Aug 31, 2021
Launch of Therapeutic Radiopharmaceutical Product, Lutathera® Injection targeting neuroendocrine tumors in Japan (FUJIFILM Toyama Chemical)
News Release Pharmaceuticals
Jun 29, 2021
$850 Million USD (¥90 Billion Yen) investment in FUJIFILM Diosynth Biotechnologies to add additional development and manufacturing capacity
News Release M&A, Investment Bio-CDMO CDMO
Jun 23, 2021
Marketing Authorization Granted for Lutathera® Injection in Japan
- The first approval in Japan for peptide receptor radionuclide treatment drug, providing a new therapeutic option for neuroendocrine tumors (FUJIFILM Toyama Chemical)
News Release Pharmaceuticals
Mär 31, 2021
FUJIFILM Healthcare starts to operate as Fujifilm Group company
News Release M&A, Investment Healthcare IT X-ray Imaging Devices Ultrasound Devices
Mär 30, 2021
Fujifilm launches “FUJIFILM COVID-19 Ag Test”, a SARS-CoV-2 antigen rapid diagnostic test with a highly-sensitive detection technology based on silver halide amplification, in Europe
News Release In Vitro Diagnostics